37th week of 2017 patent applcation highlights part 10 |
Patent application number | Title | Published |
20170258901 | LOCALIZED IMMUNOSUPPRESSION OF ALLOGRAFTS FOR PERIPHERAL NERVE REPAIR - Embodiments described herein relate to restorative solutions for segmental peripheral nerve (PN) defects using allografted PNs for stimulating PN repair. More specifically, embodiments described herein provide for localized immunosuppression (LIS) surrounding PN allografts as an alternative to systemically suppressing a patient's entire immune system. Methods include localized release of immunosuppressive (ISV) agents are contemplated in one embodiment. Methods also include localized application of immunosuppressive (ISV) regulatory T-cells (Tregs) in other embodiments. Hydrogel carrier materials for delivery of ISV agents and are also described herein. | 2017-09-14 |
20170258902 | IMMUNOGENIC PEPTIDE CONJUGATE AND METHOD FOR INDUCING AN ANTI-INFLUENZA THERAPEUTIC ANTIBODY RESPONSE THEREWITH - Immunogenic influenza hemagglutinin-derived peptide conjugates described herein induce a specific therapeutic antibody response against influenza virus. The immunogenic peptide conjugates comprise a segment from the fusion initiation region (FIR) domain of an influenza hemagglutinin protein conjugated to an immunogenic carrier protein, such asbovine serum albumin (BSA), an influenza hemagglutinin (HA) protein (i.e., full length HA), and the like. The immunogenic peptide conjugates described herein can be utilized to treat or prevent influenza infection and to prepare influenza-specific therapeutic antibodies that interfere with influenza virus-host cell membrane fusion. The peptide conjugates can be formulated in pharmaceutical compositions useful for broad spectrum treatment or prevention of influenza infections. | 2017-09-14 |
20170258903 | COMBINATION THERAPIES FOR TREATING HER2-POSITIVE CANCERS THAT ARE RESISTANT TO HER2-TARGETED THERAPIES - Methods for treating cancer patients (e.g., cancer patients resistant or intolerant to pertuzumab and ado-trastuzumab emtansine) with HER2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of a doxorubicin-loaded immunoliposome with a targeting moiety that is an anti-HER2 antibody that is not an inhibitor of HER2 signaling and an anti-cancer therapeutic comprising a doxorubicin-free anti-cancer therapeutic comprising a different anti-HER2 antibody. | 2017-09-14 |
20170258904 | Antagonism of the VIP Signaling Pathway - Inhibition of the VIP signaling pathway with VIP antagonist is contemplated. In certain embodiments, the disclosure relates to methods of enhancing the immune response to a cell therapy comprising administering a VIP antagonist to a subject in combination with a cell. In certain embodiments, the subject is diagnosed with leukemia or lymphoma. In certain embodiments, the cell is a blood cell, bone marrow cell, leukocyte, T-cell, natural killer cell, a hematopoietic stem cell, a G-CSF mobilized or non-mobilized blood mononuclear cell. | 2017-09-14 |
20170258905 | METHODS AND COMPOSITIONS FOR ENHANCING THE POTENCY OF SUPERANTIGEN MEDIATED CANCER IMMUNOTHERAPY - The invention provides methods or compositions for enhancing the potency of a targeted cancer immunotherapy in a subject by using a superantigen in combination with an immunopotentiator (for example, a PD-1 inhibitor). | 2017-09-14 |
20170258906 | VIRUS-PCION COMPLEX HAVING ENHANCED ANTITUMOR EFFECT BY USING ELECTROMAGNETIC FIELD - The present disclosure relates to a composition for transduction of a virus in a cell by using a crosslinked product of PEGylated magnetic nanoparticles and catechol grafted poly-L-lysine by application of an external magnetic field. When the composition is used, a virus may be delivered into cells more rapidly and efficiently than in intracellular uptake of a virus by CAR-mediated endocytosis. | 2017-09-14 |
20170258907 | MULTIMODE DEGRADABLE HYDROGELS FOR CONTROLLED RELEASE OF CARGO SUBSTANCES - A responsive hydrogel-based material may be used as a carrier system for the in situ delivery of various cargo substances, including bioactive moieties. The hydrogel structure, which includes photodegradable and thioether moieties in its three dimensional network, enables finely tuned local release of cargo substances as a function of the in vivo tissue environment (e.g., enzyme concentration or reducing environment) and externally applied stimuli (e.g., light) by selective spatiotemporal hydrogel degradation. | 2017-09-14 |
20170258908 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS - Methods for the treatment of a cell proliferation disorder in a subject, involving:
| 2017-09-14 |
20170258910 | COMPOSITIONS AND METHODS FOR PROTECTING SAPONIN ACTIVITY - The invention is related to compositions including saponins and saponin-protective agents and related methods. In an embodiment, a composition is included herein. The composition can specifically include a saponin composition comprising saponins and a saponin-protective agent, wherein the saponin-protective agent prevents deglycosylation of the saponins in an aqueous environment containing glycosidase enzymes. Other embodiments are included herein. | 2017-09-14 |
20170258911 | STABLE PHARMACEUTICAL FORMULATIONS OF METHYLNALTREXONE - Stable pharmaceutical compositions useful for administering methylnaltrexone are described, as are methods for making the same. Kits, including these pharmaceutical compositions, also are provided. | 2017-09-14 |
20170258912 | COMPOSITIONS AND METHODS FOR REDUCING OVERDOSE - Drug delivery formulations, uses thereof and methods of making same are provided in order to reduce the potential for abuse, misuse or improper administration of an addictive substance or any active substance and to prevent, reduce, inhibit, or delay purposeful or accidental overdose of an active substance by ingesting too many dosage forms at once, for example. | 2017-09-14 |
20170258913 | SHELF-STABLE FOAM-LIKE CONFECTIONARIES COMPRISING ERYTHRITOL AND ACTIVE INGREDIENTS - In one embodiment, a confectionary comprises 50 to 75 wt. % erythritol, 0 to 75 wt. % of at least one additional sweetener, at least one stabilizer, water, and a first active ingredient. The water may comprise 0.5 to 3 wt. % of the confectionary. The water may have a water activity of from 0.3 to 0.5. The confectionary may be aerated such that the density of the confectionary is 0.05 to 0.3 grams per cubic centimeter. | 2017-09-14 |
20170258914 | NOVEL ANTIFUNGAL COMPOSITION - There is provided a pharmaceutical composition for the treatment of fungal infection of the nail comprising a anti-fungal allylamine compound present in an amount of about 10%, an organic acid or an ester thereof, a diol and a sequestering agent where the pharmacological composition is essentially water-free | 2017-09-14 |
20170258915 | Delivery and Formulation of Engineered Nucleic Acids - Provided are formulations, compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the delivery of biological moieties, and are useful for production of proteins. | 2017-09-14 |
20170258916 | Pharmaceutical Composition Containing Sympathomimetic Amine Salt and Co-distillable Additive - A pharmaceutical composition is provided which contains a water soluble acid salt of a sympathomimetic amine, e.g., pseudoephedrine, and an additive, e.g., a volatile amine or other odorant, that is co-distillable, e.g., by steam distillation, with the sympathomimetic amine and/or its derivatives, e.g., its free base. | 2017-09-14 |
20170258917 | SOLUBILITY OF THERAPEUTIC AGENTS - Disclosed herein are methods and compositions to improve the solubility of therapeutic agents. In one embodiment, a method of improving solubility of a therapeutic agent includes mixing fullerene in a lipid solution to form a lipofullerene mixture, and mixing the therapeutic agent with the lipofullerene mixture. | 2017-09-14 |
20170258918 | AERATED CONFECTIONARIES COMPRISING SHELF-STABLE ACTIVE INGREDIENTS - In one embodiment, a confectionary comprises at least one sweetener, at least one stabilizer, at least one emulsifier, water, a first active ingredient, and an enrobing layer. The water may comprise 2 to 20 wt. % of the confectionary. The confectionary may have a water activity of from 0.45 to 0.65. The confectionary may be aerated such that the density of the confectionary is 0.7 to 1.25 grams per cubic centimeter. The confectionary may have a pH of 5.0 to 8.0. | 2017-09-14 |
20170258919 | Compositions - The invention provides a colon cleansing solution comprising:
| 2017-09-14 |
20170258920 | STABILIZER FOR HYALURONIDASE AND LIQUID FORMULATION COMPRISING HYALURONIDASE - This invention relates to a stable liquid formulation comprising hyaluronidase and a stabilizer for hyaluronidase and more particularly, to a stable liquid formulation by the addition of the stabilizer to the hyaluronidase. | 2017-09-14 |
20170258921 | Protease Triggered Release Of Molecules From Hydrogels - The invention relates to compositions comprising (i) biocompatible hydrogel and (ii) one or more therapeutic agents contained within said hydrogel; wherein the hydrogel is cross-linked utilizing a cross-linker comprising a peptide sequence that is capable of being degraded by an enzyme; the therapeutic agent being effective as a treatment of a condition related to the presence of the enzyme. | 2017-09-14 |
20170258922 | MICELLE CONTAINING EPIRUBICIN-COMPLEXED BLOCK COPOLYMER AND ANTI-CANCER AGENT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAID MICELLE APPLICABLE TO TREATMENT OF CANCER, RESISTANT CANCER OR METASTATIC CANCER - The problem addressed by the present invention is to develop a pharmaceutical having therapeutic efficacy against epirubicin-resistant tumors. The present invention provides a micelle having an anti-cancer agent disposed inside the core of the micelle formed by an epirubicin-conjugated copolymer. | 2017-09-14 |
20170258923 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING - Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them. | 2017-09-14 |
20170258924 | Ester of a Phospholipid With Conjugated Linoleic Acid for the Treatment of Psychiatric Disorders With Neuroinflammatory and Neurodegenerative Basis - An ester of a phospholipid with conjugated linoleic acid for use in the therapeutic treatment of or as a food supplement for psychiatric disorders with neuroinflammatory and neurodegenerative basis, such as depression and schizophrenia. | 2017-09-14 |
20170258925 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF - One aspect of the invention provides polymer conjugated MetAP2 inhibitors. While not being bound by any particular theory, it is believed that coupling the MetAP2 inhibitory core via the linkers described herein provides compounds with superior efficacy to the parent small molecules and superior pharmacokinetic profiles. In one aspect of the invention, the polymer conjugated MetAP2 inhibitors are useful in methods of treating disease, comprising administering to a subject in need thereof a therapeutically effective amount of a polymer conjugated MetAP2 inhibitor. | 2017-09-14 |
20170258926 | MICELLAR NANOCOMPLEX - The present invention relates to micellar nanocomplexes and a method of forming the same. The micellar nanocomplex comprises a micelle and an agent encapsulated within said micelle, where the micelle comprises a polymer-flavonoid conjugate, wherein said polymer is bonded to the B ring of said flavonoid. The micellar nanocomplex may have useful applications as a drug-delivery system. | 2017-09-14 |
20170258927 | FORMULATIONS AND DOSES OF PEGYLATED URICASE - Provided herein are methods and compositions and kits related to uricase compositions and/or compositions comprising synthetic nanocarriers comprising an immunosuppressant. Also provided herein are methods and compositions and kits for the treatment of subjects, including subjects with hyperuricemia, gout or a condition associated with gout, and for preventing gout flare. | 2017-09-14 |
20170258928 | CELL PENETRATING PEPTIDES FOR INTRACELLULAR DELIVERY OF MOLECULES - A cell-penetrating peptide characterized in that it comprises an amino acid sequence X | 2017-09-14 |
20170258929 | CANCER TREATMENT COMBINATION COMPOSITIONS, METHODS AND USES - The invention provides combinations and formulations including a luteinizing hormone-releasing hormone (LHRH) or a LHRH analog; and curcumin or a curcumin analog. LHRH or LHRH analog can be fused or conjugated to a curcumin or curcumin analog. Invention combinations and formulations can also include an anti-cell proliferative drug. Invention combinations and formulations can be used for inhibiting proliferation of a cell; treating a hyperproliferative disorder; and treating a neoplasia, tumor, cancer or malignancy. | 2017-09-14 |
20170258930 | SKIN PENETRATING PEPTIDES (SPPS) AND METHODS OF USE THEREFOR - The present disclosure provides peptides and peptide compositions, optionally in the from of a vaccine, which facilitate the delivery of an active agent or an active agent carrier wherein the compositions are capable of penetrating the stratum corneum (SC) and/or the cellular membranes of viable cells. Also provided are methods of employing the peptides and peptide compositions to deliver active agents; treat diseases or disorders; and inducing immune responses. | 2017-09-14 |
20170258931 | STABLE PEPTIDE-CONJUGATED ASCORBIC ACID DERIVATIVE, METHOD FOR PREPARING SAME, AND COSMETIC COMPOSITION COMPRISING SAME - The present invention provides a stable peptide-conjugated, ascorbic acid derivative, a method for preparing the same, and a cosmetic composition comprising the same as an active ingredient. The stable peptide-conjugated ascorbic acid derivative of the present invention has both the effect of whitening the skin by inhibiting melanin production and the effect of reducing skin wrinkles by activating collagen production, and may be used in a cosmetic composition. | 2017-09-14 |
20170258932 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS - The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells. | 2017-09-14 |
20170258933 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF MOLECULES INTO LIVE CELLS - The present disclosure provides methods and compositions related to the cytosolic delivery of proteins and cell-impermeable small molecules into live cells using an endosomolytic dimer of cell-penetrating peptide TAT. | 2017-09-14 |
20170258934 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES - The present disclosure relates to the use of antibody-drug conjugates (ADCs) comprising pyrrolobenzodiazepine (PBD) dimers and anti-CD25 antibodies for use in treating disorders characterized by the presence of CD25+ve cells. | 2017-09-14 |
20170258935 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ERB B2/NEU POSITIVE DISEASES - Disclosed herein are anti-ERB B2/NEU antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods relating to the preparation and uses of such drug conjugates to treat ERB B2/NEU positive cells in cancers are provided. | 2017-09-14 |
20170258936 | Tunable pH-Sensitive Linker for Controlled Drug Release - A novel acid labile linker for targeted delivery and/or controlled phosphoryl hydroxypropylglycine release of agents is introduced herein. There is further disclosed a method of developing a therapeutic or diagnostic conjugate for targeted cell-specific delivery. More specifically, the invention is focused on linkers used to deliver anticancer agents to specific tumor cells. | 2017-09-14 |
20170258937 | PHARMACEUTICAL COMPOSITION, PREPARATION AND USES THEREOF - The invention relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle, said biocompatible nanoparticle comprising at least one oligomer of albumin (n≧2) or consisting in an oligomer of albumin, and of (ii) at least one compound of interest, typically at least one pharmaceutical compound, to be administered to a subject in need of such at least one compound of interest, wherein the at least one nanoparticle potentiates the at least one compound of interest efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm. The invention also relates to such a composition for use for administering the at least one compound of interest in a subject in need thereof, wherein the at least one biocompatible nanoparticle and the at least one compound of interest are to be administered in said subject sequentially, typically between more than 5 minutes and about 72 hours one from each other. | 2017-09-14 |
20170258938 | EXOSOME TRANSFER OF NUCLEIC ACIDS TO CELLS - Methods for introducing nucleic acids to cells via exosomes for use in gene modulation and therapy, such as for gene silencing and to introduce genetic material into cells to compensate for abnormal genes or to induce or repress a process in the recipient cell. | 2017-09-14 |
20170258939 | Staining Composition - The invention is directed to a staining composition and to the use of the staining composition in staining ocular tissue. In a first aspect, the invention provides a staining composition comprising a vital dye and a density increasing compound chosen from the group consisting of water soluble polymers and small inert molecules. | 2017-09-14 |
20170258940 | TRANSGENIC MOUSE MODEL FOR CONDITIONAL FKBP51 EXPRESSION AND RELATED METHODS - The subject invention pertains to transgenic non-human animals comprising a transgenic nucleotide sequence, integrated into the genome of the animals, comprising a nucleotide sequence encoding human FKBP51 operably linked to a tetracycline response element. In some embodiments, the transgenic animal comprises an additional transgenic nucleotide sequence, integrated into the genome of the animal, comprising a nucleotide sequence encoding a tetracycline transactivator (tTA) operably linked to a promoter; wherein the tTA is expressed upon activation of the promoter and binds the tetracycline response element, thereby causing expression of FKBP51. The invention also pertains to methods for screening for agents for the prevention and/or treatment of psychiatric disorders, such as depression. | 2017-09-14 |
20170258941 | TOPICAL APPLICATION OF NERVE LABELING DYES FOR IMAGE-GUIDED SURGERY - The present invention relates to a topical agent that binds specifically to myelin basic protein and its method of use and determining myelination in the subject by detecting the agent present in the subject. A kit containing the agent or its derivatives for use in detecting myelin basic protein is also provided. | 2017-09-14 |
20170258942 | METHODS FOR TREATING AND DIAGNOSING BLINDING EYE DISEASES - This invention relates to, in part, methods and compositions that are useful for the diagnosis, treatment, or prevention of a blinding eye disease, including in the discovery of drugs that are efficacious against these diseases. Diseases include, for example, age related macular degeneration and reticular pseudodrusen disease, and the methods described herein include, for example, the method named delayed near infrared analysis (DNIRA). | 2017-09-14 |
20170258943 | Using Heavy Water as a Contrast Agent for Hydrogen Magnetic Resonance Imaging - A method of using an imaging contrast agent is provided for hydrogen magnetic resonance imaging (H MRI). The agent uses replacement and chemical exchange of hydrogen (H) and deuterium (D) on obtaining MRI images for comparison. An isotonic physiologic saline solution with deuterium oxide (D | 2017-09-14 |
20170258944 | Formulations of Metal Complexes - The present invention relates to a method of preparation of formulations of gadolinium metal complexes of the macrocyclic chelator DOTA, which further comprise a small excess of free DOTA. The method uses controlled conditions such that excess gadolinium is present as a precipitate of gadolinium oxide, with filtration to remove the excess, prior to the addition of a defined excess of DOTA chelator. Also provided is a method of preparation of MRI contrast agents based on Gd-DOTA. | 2017-09-14 |
20170258945 | LANTHANIDE COMPLEX FORMULATIONS - The present invention relates to a method of removal of metal ion impurities, such as calcium, from lanthanide metal complexes of macrocyclic chelators. The method uses a scavenger resin to remove metal ions, displaced from chelator, by an excess of lanthanide ions. Also provided is a method of preparation of MRI contrast agents, from the purified lanthanide metal complex, by the addition of a defined excess chelator. | 2017-09-14 |
20170258946 | LIPID-ENCAPSULATED GAS MICROSPHERE COMPOSITIONS AND RELATED METHODS - The invention provides, inter alia, improved lipid formulations used to generate lipid-encapsulated gas microspheres, and methods of their use. | 2017-09-14 |
20170258947 | METHODS AND APPARATUS FOR SYNTHESIZING IMAGING AGENTS, AND INTERMEDIATES THEREOF - The present invention generally relates to methods and system for the synthesis of imaging agents, and precursors thereof. The methods may exhibit improved yields and may allow for the large-scale synthesis of imaging agents, including imaging agents comprising a radioisotope (e.g., | 2017-09-14 |
20170258948 | NOVEL PD-L1 BINDING POLYPEPTIDES FOR IMAGING - Provided herein are novel | 2017-09-14 |
20170258949 | RADIOACTIVE COMPOSITIONS AND METHODS FOR THEIR THERAPEUTIC USE - This invention concerns a pharmaceutically-acceptable composition of radioactive metals, which are used for treating various diseases in animals or humans, such as cancer and arthritis. | 2017-09-14 |
20170258950 | LIPID STERILISATION METHOD - The present invention relates to a method for sterilisation of phospholipid suspensions, useful in the preparation of ultrasound contrast agent precursors comprising phospholipid-stabilised perfluorobutane microbubbles. The method provides sterility assurance, without undue thermal degradation of the phospholipid. The method is also amenable to commercial scale manufacture. Also provided are methods of preparing kits and ultrasound contrast agents incorporating the sterilisation method of the invention. | 2017-09-14 |
20170258951 | STERILISATION CONTAINER, METHOD OF STERILISATION AND STERILISATION APPARATUS - Disclosed is a steam sterilizer, and a single use/disposable container for use in the steriliser and a sterilisation method. The container is a rigid or semi-rigid container having a sealable elongate conduit through which steam sterilant may be introduced into the container and steam sterilant and condensate may be removed from the container. Once one or more items to be sterilised are placed in the container a cover is sealed over the mouth of the container. The steam steriliser has a sterilisation chamber adapted to receive the container and provide sterilant within and around the container. Sterilant is provided to the container via the conduit which is sealed at the end of the sterilisation process. | 2017-09-14 |
20170258952 | BODY FLUID DRAINAGE DEVICE AND METHOD - Method for sterilising a body fluid drainage system for handling a body fluid ex vivo. The body fluid drainage system comprises a chamber. The method comprises the steps providing a container containing a surface protective fluid to be released into the chamber of the body fluid drainage system, subjecting the container to radiation sterilisation, inserting the container into the chamber of the body fluid drainage system, and subjecting the chamber containing the container to gas sterilisation. A body fluid drainage system for handling a body fluid ex vivo. The body fluid drainage system comprises a chamber. The body fluid drainage system further comprises a container containing a surface protective fluid. The container is arranged to release the surface protective fluid into the chamber. The surface protective fluid is sterilised by radiation sterilisation. An outer surface of the container and at least the chamber of the body fluid drainage system is sterilised by gas sterilisation. | 2017-09-14 |
20170258953 | ELECTRONEGATIVE FIBRE FOR USE IN THE HEALING OF WOUNDS - A subject of the present invention is a material comprising at least one electronegative fiber having a negative charge density of between 0.01 and 5 mmol/g and a liquid absorption capacity of less than 9.5 g of physiological saline per g of fiber, for the use thereof in wound healing, and preferentially in wound cleaning. Another subject of the invention is a medical device, such as a dressing or a bandage, comprising such a material. | 2017-09-14 |
20170258954 | FLOWABLE COLLAGEN-BASED HEMOSTAT AND METHODS OF USE - The invention relates to methods for fabricating a flowable hemostatic composition. The invention also relates to hemostatic compositions and methods for promoting wound healing. In various embodiments, the hemostatic compositions comprise crosslinkable collagen molecules having a porosity controlled by the ratio of weight percent collagen solids to weight percent crosslinker when crosslinking the collagen. In other embodiments, the hemostatic compositions comprise crosslinkable collagen molecules having a porosity controlled by the temperature and rate of freezing when drying the composition during fabrication. In some embodiments, the compositions contain additional agents, including biological agents. | 2017-09-14 |
20170258955 | ABSORBENT ARTICLE WITH ACTIVATABLE MATERIAL - Material webs suitable for use in conjunction with disposable absorbent articles are disclosed herein. The material webs comprise a melt additive that when subjected to thermal energy may be encouraged to bloom across the entirety of the web or in localized areas of the web where localized thermal energy is applied. | 2017-09-14 |
20170258956 | Medical Dressing - A medical dressing is disclosed, comprising a substrate comprising a first chemical compound, said substrate having a first surface, wherein said medical dressing further comprises an adhesive layer having a skin-facing surface to adhere said medical dressing to a dermal surface, wherein at least a portion of said skin-facing surface comprises a coating comprising a second chemical compound. Also disclosed is a method of manufacturing such a medical dressing. | 2017-09-14 |
20170258957 | Medical Dressing - A medical dressing ( | 2017-09-14 |
20170258958 | DEGRADABLE HAEMOSTAT COMPOSITION - In one aspect, the present invention includes a haemostat composition that includes a chitosan, chitosan salt or chitosan derivative, and a physiologically acceptable acid, which is present in the amount of 45-70% by weight of the haemostat composition. The haemostat composition is able to safely gradually and fully degrade in a human or animal body within about 30 days and so can be utilised by physicians to stem a flow of blood and promote healing both after as well as during surgical procedures. | 2017-09-14 |
20170258959 | DEGRADABLE HAEMOSTAT COMPOSITION - In one aspect, the present invention includes a haemostat composition that includes a chitosan, chitosan salt or chitosan derivative, and a physiologically acceptable acid selected from the group consisting of lactic acid, formic acid, acetic acid, ascorbic acid, halogen acetic acids, propanoic acid, propenoic acid, acrylic acid, glyoxylic acid, pyruvic acid or a hydroxy propionic/butanoic acid, and combinations of any two or more thereof; or one or more acids selected from hydrochloric acid and sulphuric acid. The haemostat composition is able to safely gradually and fully degrade in a human or animal body within about 30 days and so can be utilised by physicians to stem a flow of blood and promote healing both after as well as during surgical procedures. | 2017-09-14 |
20170258960 | INORGANICALLY SURFACE-MODIFIED POLYMERS AND METHODS FOR MAKING AND USING THEM - In alternative embodiments, the invention provides articles of manufacture comprising biocompatible nanostructures comprising PolyEther EtherKetone (PEEK) surface-modified (surface-nanopatterned) to exhibit nanostructured surfaces that promote osseointegration and bone-bonding for, e.g., joint (e.g., knee, hip and shoulder) replacements, bone or tooth reconstruction and/or implants, including their use in making and using artificial tissues and organs, and related, diagnostic, screening, research and development and therapeutic uses, e.g., as primary or ancillary drug delivery devices. In alternative embodiments, the invention provides biocompatible nanostructures that promote osseointegration and bone-bonding for enhanced cell and bone growth and e.g., for in vitro and in vivo testing, restorative and reconstruction procedures, implants and therapeutics. | 2017-09-14 |
20170258961 | COMPOSITION FOR MODIFYING MYOCARDIAL INFARCTION EXPANSION - A bioscaffolding can be formed within a post-myocardial infarct region sufficient to cause attenuation of a rate of myocardial infarct expansion. A bioscaffolding may further be formed in the post-myocardial infarct region to cause an increase in posterior left ventricular wall thickness. The gel or bioscaffolding can be formed from a mixture of gel components of different gelation systems. For example, a bioscaffolding can be formed by mixing at least two different components of at least two different two-component gelation systems to form a first mixture and by mixing at least two different components (other than the components that make up the first mixture) of the at least two different two-component gelation systems to form a second mixture. | 2017-09-14 |
20170258962 | BONE OR OSTEOCHONDRAL TISSUES AND USES THEREOF - The present disclosure provides modified bone and osteochondral tissues, methods of preparing modified bone and osteochondral tissues, and methods of using the modified bone or osteochondral tissues to repair bone or osteochondral defects in a subject. | 2017-09-14 |
20170258963 | CATIONIC STEROIDAL ANTIMICROBIAL COMPOSITIONS FOR THE TREATMENT OF DERMAL TISSUE - This disclosure relates to dermal treatment compositions, such as dermal fillers and tissue glues, and injectable compositions that incorporate one or more cationic steroidal antimicrobials (CSAs). The CSAs are incorporated into the dermal treatment compositions to provide effective antimicrobial, anti-inflammatory, analgesic, anti-swelling and/or tissue-healing properties. A treatment composition includes a component formed from a biologically compatible material suitable for injection into and/or application onto tissue at a treatment site. One or more CSA compounds are mixed with the biologically compatible material so that the one or more CSA compounds are incorporated within the composition, forming a reservoir of CSA compounds within the resulting bolus of the treatment composition after injection and/or application. | 2017-09-14 |
20170258964 | Porous Structures of Microbial-Derived Cellulose In Vivo Implantation - This invention elates to polysaccharide materials and more particularly to microbial-derived cellulose having the porosity and containing pores of the desired size making it suitable for cellular infiltration during implantation and other desirable properties for medical and surgical applications. The invention also relates to the use of porous microbial-derived cellulose as tissue engineering matrices, human tissue substitutes, and reinforcing scaffolds for regenerating injured tissues and augmenting surgical procedures The invention outlines various methods during and after fermentation to create porous microbial cellulose capable of allowing cell infiltration while preserving the physical properties of the microbial-cellulose. | 2017-09-14 |
20170258965 | TISSUE GRAFT - The present invention is directed to a method of producing a tissue graft, comprising at least steps of providing a gel, seeding the gel with cells of at least a first and/or cells of a second type, and culturing of the cells of the first and/or cells of the second type in said gel until the formation of at least one first biostructure in the gel by the cells of the first type and/or the cells of the second type. | 2017-09-14 |
20170258966 | MEDICAL DEVICE, AND METHOD FOR PRODUCING MEDICAL DEVICE - A medical device includes a base layer, and a lubrication layer supported on at least a part of the base layer, wherein the lubrication layer contains a block copolymer (A) composed of a first constituting unit derived from a reactive monomer that has an epoxy group and a second constituting unit derived from at least one hydrophilic monomer selected from the group consisting of acrylamide and an acrylamide derivative, and a polymer (B) composed of a constituting unit derived from at least one hydrophilic monomer selected from the group consisting of acrylamide and an acrylamide derivative, wherein the block copolymer (A) is contained in a proportion of 20 to 80% by weight relative to the total weight of the block copolymer (A) and the polymer (B), and wherein the block copolymer (A) is crosslinked or polymerized to form a mesh structure. | 2017-09-14 |
20170258967 | COMPOSITIONS AND METHODS FOR DELIVERING AN AGENT TO A WOUND - The invention provides compositions featuring chitosan and polyethylene glycol and methods for using such compositions for the local delivery of biologically active agents to an open fracture, complex wound or other site of infection. Advantageously, the chitosan-PEG compositions can be loaded with one or more antimicrobial agents, including hydrophobic agents, and can be tailored to the needs of particular patients at the point of care (e.g., in a surgical suite, clinic, physician's office, or other clinical setting). | 2017-09-14 |
20170258968 | DEVICE FOR FIXING BIOLOGICAL SOFT TISSUE, AND METHOD FOR PRODUCING SAME - A device for fixing biological soft tissue is endowed with strength and deformation performance for being used as a device for coupling biological soft tissue that has been cut or separated due to an incision or the like during a surgical procedure, and is completely degraded in vivo and discharged after adhesion of the soft tissue or after healing of the incision tissue. The device is composed of a ternary Mg alloy material of Mg—Ca—Zn. In the Mg alloy material, the Ca and Zn are contained within the solid-solubility limit with respect to the Mg. The remainder is composed of Mg and unavoidable impurities. The Zn content is 0.5 at % or less. The Ca and Zn content has a relationship of Ca:Zn=1:x (where x is 1 to 3) by atom ratio. The crystal grain structure is equiaxed, the crystal grain size according to linear intercept being 30 to 250 μm. | 2017-09-14 |
20170258969 | Process for the Production of Storable Implants with an Ultrahydrophilic Surface - The present invention concerns a process for the production of implants with an ultrahydrophilic surface as well as the implants produced in that way and also processes for the production of loaded, so-called bioactive implant surfaces of metallic or ceramic materials, which are used for implants such as artificial bones, joints, dental implants or also very small implants, for example what are referred to as stents, as well as implants which are further produced in accordance with the processes and which as so-called “delivery devices” allow controlled liberation, for example by way of dissociation, of the bioactive molecules from the implant materials. | 2017-09-14 |
20170258970 | POLYMER-DRUG CONJUGATE BASED ON A POLYISOOLEFIN-BASED COPOLYMER - A polymer-drug conjugate, which can be used in medical applications such as stents, has at least one active agent conjugated through a carboxylic acid moiety to a copolymer derived from at least one isoolefin monomer and at least one copolymerizable monomer, where the copolymerizable monomer is at least one multiolefin monomer, a β-pinene monomer or a mixture thereof. Such conjugates show improved adhesion to stainless steel and a substantial decrease in burst release of paclitaxel form a drug eluting stent (DES). | 2017-09-14 |
20170258971 | APPARATUSES AND METHODS FOR DETECTING LEAKS IN A NEGATIVE PRESSURE WOUND THERAPY SYSTEM - Leak location devices and methods of using leak location devices that can be used in conjunction with negative pressure wound therapy systems are disclosed. In some embodiments, a leak location device can include a microphone for detecting sound pressure produced by a leak. Detected sound pressure can be compared to a threshold, which can correspond to background or ambient sound pressure. Background or ambient sound pressure can correspond to sound produced by a negative pressure source. The leak detection device can include a display configured to visually depict the detected sound, and a light source which creates a visual depiction of the coverage angle of the microphone. | 2017-09-14 |
20170258972 | NEGATIVE PRESSURE DRESSING AND METHOD OF USING SAME - Disclosed herein are apparatuses and methods for treating a wound by applying reduced or negative pressure to the wound. The apparatus can include a wound cover, a fluid collection container, a vacuum pump, an inflation pump, and one or more conduits. The wound cover can be configured to move between at least a relatively rigid, generally raised position and a relatively flexible, generally collapsed position according to a predetermined program or in response to input from a user or one or more sensors. In some embodiments, the wound cover can be configured to move between at least the relatively rigid, generally raised position and the relatively flexible, generally collapsed position by adjusting the air pressure in one or more channels in the wound cover or by adjusting the length of piezoelectric or other length changing material supported by the wound cover. | 2017-09-14 |
20170258973 | FLEXIBLE REDUCED PRESSURE TREATMENT APPLIANCE - A wound treatment appliance is provided for treating all or a portion of a wound. In some embodiments, the appliance includes an impermeable flexible overlay for applying a reduced pressure to the covered portion of the wound. The wound treatment appliance may also include a vacuum system to supply reduced pressure to the wound in the area under the flexible overlay, a wound packing means to prevent overgrowth of the wound or to encourage growth of the wound tissue into an absorbable matrix including the wound packing means, a suction drain, a collection chamber to collect and store exudate from the wound, and/or a suction bulb which may be used to provide a source of reduced pressure to an impermeable overlay that covers all or a portion of the wound. Finally, methods are provided for using various embodiments of the wound treatment appliance. | 2017-09-14 |
20170258974 | PREVENTION OF AORTIC VALVE FUSION - Materials and methods related to blood pump systems are described. These can be used in patients to, for example, monitor arterial pressure, measure blood flow, maintain left ventricular pressure within a particular range, avoid left ventricular collapse, prevent fusion of the aortic valve in a subject having a blood pump, and provide a means to wean a patient from a blood pump. | 2017-09-14 |
20170258975 | Methods and Systems for Detecting an Occlusion in a Blood Circuit of a Dialysis System - The present specification describes systems and methods for detecting an occlusion in a tubing carrying a patient's blood through a manifold and into a dialyzer in a dialysis system. A controller measures pressures value of the blood at a predetermined point after exiting the manifold and before entering the dialyzer, calculates a historical running average, calculates a weighted sum of the most recent pressure values, and determines whether to trigger an occlusion alarm based on a function of the historical running average and the weighted sum of the most recent pressure values. | 2017-09-14 |
20170258976 | METHOD OF DISPLAYING A PREDICTED STATE, MEDICAL APPARATUS AND COMPUTER PROGRAM - A method of displaying a predicted state of a medical apparatus, and a medical apparatus employing the method are disclosed. The method comprises receiving a sensor signal from a sensor of the medical apparatus, filtering the sensor signal by an adaptive filter such that a predicted signal is achieved, determining a state from the predicted signal, and displaying an indication through a user interface of the medical apparatus based on the determined state. | 2017-09-14 |
20170258977 | HEMOFILTRATION DEVICE - A hemofiltration device capable of surely performing highly-efficient hemofiltration. The hemofiltration device of the present invention is adapted to be implanted in a mammalian body for filtering blood, and includes a blood flow path layer having a blood flow path, a filtrate flow path layer having a filtrate flow path disposed along the blood flow path, and a filtration membrane interposed between the blood flow path layer and the filtrate flow path layer, for filtering the blood flowing through the blood flow path. A filtrate outlet of the filtrate flow path is provided at a position closer to a blood outlet than to a blood inlet of the blood flow path. The blood inlet, blood outlet, and filtrate outlet are provided only on one side or separately on opposite sides of a main body portion in the direction in which the layers are stacked. | 2017-09-14 |
20170258978 | GATED-CONCENTRIC ARTIFICIAL LUNG - An artificial lung including a housing having a circular outer wall being enclosed by a first surface and a second surface to define an interior volume, a blood inlet port to permit inlet flow of blood to the housing, a blood outlet port to permit outlet flow of the blood from the housing, a gas inlet port to permit inlet flow of a gas to the housing, a gas outlet port to permit outlet flow of the gas from the housing, and a plurality of baffles concentrically disposed within the housing. The baffles are positioned to define a flow path between the blood inlet port and the blood outlet port. Each of the baffles includes a gate opening to permit flow of the blood along the flow path. A fiber bundle is disposed between the baffles within the flow create mixing and improve gas exchange efficiency. | 2017-09-14 |
20170258979 | Methods and Systems of Generating Rapidly Varying Pressure Amplitudes in Fluidic Circuits in a Dialysis Treatment System - The present specification describes a modular, portable hemofiltration system, for providing improved clearance levels of blood toxins, which includes at least one roller pump that is designed and operated to generate a rapidly varying pressure profile of fluid within at least a blood circuit of the hemofiltration system. | 2017-09-14 |
20170258980 | PRESSURE SENSING EXTRACORPOREAL CIRCULATION DEVICE - An extracorporeal blood circulation system reduces the risk of generation of air bubbles entering the circulation circuit associated with placement of a pressure sensor that detects a patient's blood pressure at a blood removal line. Instead of directly measuring pressure at the blood removal line where suction exists, an intermediate part pressure sensor detects pressure between a centrifugal pump and an oxygenator. A controller identifies a discharge pressure specific to the centrifugal pump based on a rotation speed of the pump and a blood flow rate. The discharge pressure and the intermediate pressure values are combined to estimate the pressure at the blood removal line. | 2017-09-14 |
20170258981 | BLOOD PUMP SYSTEMS AND METHODS - The present invention relates to a rotary blood pump with a double pivot contact bearing system with an operating range between about 50 mL/min and about 1500 mL/min, wherein the force on the upper bearing is less than 3N during operating speeds up to 6000 rpm. The rotary blood pump is part of a blood pump system that includes blood conduit(s), a control system with optional sensors, and a power source. Embodiments of the present invention may include elements designed to increase the length of time the rotary blood system can operate effectively in vivo, including wear resistant bearing materials, a rotor back plate for magnetic attraction of the rotor to reduce bearing pivot bearing forces and wear, a rotor size and shape and a bearing gap that combine to create a hydrodynamic bearing effect and reduce bearing pivot bearing forces and wear, improved intravascular conduits with increased resistance to thrombosis, conduit insertion site cuffs to resist infection, and conduit side ports amenable to the easy insertion of guidewire and catheter-based medical devices to treat conduits and related blood vessels to maintain blood pump system function over time. | 2017-09-14 |
20170258982 | SYSTEM AND METHODS FOR PRE-INJECTION PRESSURE PREDICTION IN INJECTION PROCEDURES - A method of predicting peak pressure within a fluid path, which includes a tubing set and a catheter into which at least one fluid is introduced under pressure by a pressurizing system of a fluid injection apparatus, includes (a) inputting an initial injection protocol into the fluid injection apparatus according to which the at least one fluid is intended to be introduced into the fluid path; (b) predicting an expected peak pressure level that would result in the fluid path if the initial injection protocol were to be used as intended to introduce the at least one fluid into the fluid path. The expected peak pressure level is determined before commencement of the initial injection protocol according to at least one model on the basis of a flow rate of the at least one fluid, at least one catheter characteristic, and a viscosity of the at least one fluid. The at least one model is determined experimentally for a plurality of fluids of different viscosities, for a plurality of catheters of different catheter characteristics, and for at least one tubing set of like kind to the tubing set of the fluid path. | 2017-09-14 |
20170258983 | ILLUMINATED MEDICAL INFUSION - Disclosed are various embodiments for illuminated medical infusion including, for example, a medical infusion system which includes a source of illumination and an illuminating infusion line and wherein the illuminating infusion line includes an integrated fluid transmission channel and light transmission channel. | 2017-09-14 |
20170258984 | MEDICAL BEDSIDE SAFETY MODULAR APPARATUS AND METHOD - A medical line organizer that can include multiple attachable guides for separating and visually distinguishing between attached medical line guides is provided. The guides can be attached to each other or to one or more couplers for attachment to a structure. Various identification techniques can be used to distinguish the guides from each other for identification of individual lines. Additional guides or markers with similar indicia can be placed on the lines to aid in identifying the path of a line within a particular guide. | 2017-09-14 |
20170258985 | SYRINGE INFUSION PUMP SECURITY - An infusion pump can include a syringe receptacle, a retention mechanism, a drive mechanism, and a keyed lock. The retention mechanism can inhibit removal of the syringe from the receptacle when in an engaged state, and enable removal of the syringe when in a disengaged state. The drive mechanism can include a pusher to selectively couple to a thumb press of the syringe, a motor coupleable to the pusher, and a clutch to couple and decouple the motor to the pusher. The keyed lock can operate in coordination with the retention and drive mechanisms such that, if: the keyed lock is locked, the retention mechanism is in the engaged state, and the pusher is coupled to the thumb press of the syringe, then as long as the keyed lock remains locked, the retention mechanism is constrained to the engaged state and the clutch to the coupled state. | 2017-09-14 |
20170258986 | Pump Infusion System - An infusion pump system comprises a pump for infusing a drug into a patient, a storing unit for storing therapy data, drug data, protocol data, profile data, care type data, and feedback data received from said pump and/or other sources including information about particularities of therapies already carried out or currently running, an input unit for selecting therapy data, drug data, profile data, and care type data, an associating unit for associating the selected therapy data, drug data, profile data and care type data provided by said input unit and further adapted to determine based on said association specific protocol data and specific feedback data, wherein said storing unit also stores said association with said specific protocol data and said specific feedback data; and an output unit for outputting said specific protocol data with said specific feedback data. | 2017-09-14 |
20170258987 | TRIGGERING INJECTION STATUS INFORMATION DISPLAY ON A MOBILE DEVICE VIA TAPPING THE HOUSING OF A SKIN-ATTACHABLE DRUG INJECTION DEVICE - A skin attachable drug injection device ( | 2017-09-14 |
20170258988 | APPARATUS FOR SUBRETINAL ADMINISTRATION OF THERAPEUTIC AGENT VIA A CURVED NEEDLE - An apparatus includes a body, a cannula, and a needle. The cannula is flexible and extends distally from the body. The needle is slidably disposed in the cannula. The needle includes a sharp distal tip and a curved portion. The needle is configured to translate relative to the cannula between a proximal position and a distal position. The distal tip is configured to be positioned inside the cannula when the needle is in the proximal position. The distal tip is configured to be positioned outside the cannula when the needle is in the distal position. The needle is resiliently biased to extend along a curve through the curved portion. | 2017-09-14 |
20170258989 | INSERTION DEVICE FOR INSERTION SET - An insertion device for use with an insertion set is provided. The insertion device includes a first housing having a rail. The insertion device includes a hub having a first end coupled to the rail and a second end including a projection. The hub is movable relative to the first housing along the rail. The insertion device includes a locking carrier in the first housing and movable between a first position and a second position. The locking carrier is coupled to the projection in the first position and the projection is released in the second position. The insertion device includes a second housing coupled to the insertion set and surrounding at least a portion of the first housing to define a gap. The locking carrier is received in the gap in the second position to release the projection of the hub and to enable the insertion set to be uncoupled. | 2017-09-14 |
20170258990 | PROTECTIVE COVER TYPE SAFETY DEVICE FOR SYRINGES - A protective cover type safety device for syringes includes a first buckle seat, a second buckle seat which can be engaged with the first buckle seat, and a protective cover which is pivotably connected with the first buckle seat. The first buckle seat and the second buckle seats are clamped and positioned to a needle seat of a syringe, and the protective cover is able to swing between a first position and a second position, and limited at a third position. The protective cover at the third position covers a needle body of the syringe to prevent the needle body from being exposed or piercing or hurting people. | 2017-09-14 |
20170258991 | VALVE AND A METHOD FOR ADMINISTERING A PLURALITY OF DRUG FLUIDS - A valve and a method for administering a plurality of drug fluids to a patient are disclosed. For each drug fluid, the valve may be rotated into a selected drug position associated with the drug fluid. With the valve being in the selected drug position, a backpriming may be performed of a connector line of a drug container containing the drug fluid. Thereafter, the drug fluid may be administered with the valve being in the same selected drug position. Thereafter, the valve may be flushed, optionally while maintaining the same selected valve position. | 2017-09-14 |
20170258992 | INJECTION PUMP CONTROL METHOD, CONTROL UNIT, AND INJECTION PUMP - Disclosed herein are method for controlling an insulin injection pump, a related control unit, and an injection pump. The control unit comprises an expected plasma insulin concentration value acquiring module, a current subcutaneous and interstitial insulin concentration value acquiring module, a supposed injection value acquiring module, an injection instruction sending module, and a counting module. The injection pump comprises a pump body and the control unit. The control unit is disposed in the pump body. | 2017-09-14 |
20170258993 | FORCE SENSING RESISTOR FOR LIQUID LOW-VOLUME DETECTION AND OCCLUSION SENSING AND METHODS AND APPARATUSES FOR FLOW SENSING ALONG FLUID PATH IN FLUID DELIVERY DEVICE - A system and method is provided for detecting fluid low-volume and occlusion in a device using force sensing resistor (FSR) sensor. One or more force sensing resistors are positioned in communication with a fluid channel at one or more of a pump intake and pump outlet to detect pressure in the fluid channel. The pressure is detected through communication with the force sensing resistor and indicates an irregular system condition including but not limited to, fluid low-volume level and occlusion. Also provided are a fluid flow sensor (e.g., FSR or MEMS sensor) disposed relative to an embedded fluid channel in the base of a wearable medicine delivery pump. | 2017-09-14 |
20170258994 | INJECTION DEVICES TRIGGERED BY MECHANICAL KEY - An injection device ( | 2017-09-14 |
20170258995 | SYSTEMS FOR DISPENSING A MEDICAMENT TO A SUBJECT AND RELATED METHODS - Embodiments disclosed herein are directed to systems and methods of dispensing one or more medicaments to a subject. The systems and methods utilize at least one flexible compression garment having one or more medicament dispensers therein. | 2017-09-14 |
20170258996 | DRUG DELIVERY SYSTEMS AND METHODS - Drug delivery systems and methods are disclosed herein. In some embodiments, a drug delivery system can be configured to deliver a drug to a patient in coordination with a physiological parameter of the patient (e.g., the patient's natural cerebrospinal fluid (CSF) pulsation or the patient's heart or respiration rate). In some embodiments, a drug delivery system can be configured to use a combination of infusion and aspiration to control delivery of a drug to a patient. Catheters, controllers, and other components for use in the above systems are also disclosed, as are various methods of using such systems. | 2017-09-14 |
20170258997 | SYSTEM, METHOD AND ARTICLE FOR CONTROLLING THE DISPENSING OF INSULIN - An integrated circuit includes circuitry to control a process. The process includes adjusting fuzzy-logic control parameters based on received and retrieved blood glucose-related data, predicting blood glucose levels based on the received blood-glucose-related data, and generating control signals to control dispensing of insulin based on the received blood glucose-related data and the fuzzy-logic control parameters. The process may include predicting blood glucose levels based on the retrieved blood glucose-related data. The process may include transitioning between a post-meal correction protocol and a fasting protocol. The process may include transitioning from a post-meal correction protocol to a fasting protocol when a fasting criteria is satisfied. | 2017-09-14 |
20170258998 | INJECTION DEVICE - An injection device comprising a housing in which can be mounted a syringe comprising
| 2017-09-14 |
20170258999 | Drug Delivery Device with Cartridge Centring Feature - Drug delivery device adapted to receive a cartridge, comprising a piston driver adapted to expel an amount of drug from a received cartridge, and a base member adapted to engage a cartridge and position the cartridge relative to the piston driver, the base member comprising a main portion with a central passage, a portion of the piston driver being arranged axially displaceable through the passage, the piston driver distal end being arranged distally of the central passage, and flexible centring means adapted to receive the proximal end of a cartridge and centre it relative to the central opening and thereby to the piston driver. | 2017-09-14 |
20170259000 | APPARATUS FOR REINFORCING SYRINGE CARTRIDGE - An apparatus for transdermal injection includes a collet configured to transition between first and second states. In the first state, the collet receives a cartridge with a predetermined elongate shape. In the second state, an inner surface of the collet substantially conforms to the predetermined elongate shape of the cartridge such that expansion of the cartridge, when the cartridge is pressurized, is substantially uniformly opposed. | 2017-09-14 |
20170259001 | SLEEVE FOR REINFORCING SYRINGE CARTRIDGE - An apparatus for transdermal injection includes a sleeve including a proximal end, a distal end, and an inner wall surface extending along the sleeve from a first opening at the proximal end to a second opening at the distal end. The inner wall surface forms a channel in the sleeve, the channel having a first portion with a substantially frustoconical shape. The channel of the sleeve is configured to receive a substantially frustconically shaped injection cartridge, to substantially uniformly support the injection cartridge during a transdermal injection operation, and to prevent movement of the injection cartridge out of the distal end of the sleeve. | 2017-09-14 |